Cancer Cell

Papers
(The H4-Index of Cancer Cell is 95. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity1024
Molecular subtyping in urothelial carcinoma treatment675
Simplifying clinical use of TCGA molecular subtypes through machine learning models669
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma532
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function418
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies394
Standing at the Crossroads391
Oncogenic mutations drive intestinal cancer initiation through paracrine remodeling388
Stem-cell-like T cells have a specific entry gate to the tumor350
Cholesterol atlas of tumor microenvironment provides route to improved CAR-T therapy349
Dietary modulation of the gut microbiome as an immunoregulatory intervention346
Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy302
Breaching B cell tolerance in the tumor microenvironment302
A Malignant Case of Arrested Development: Cancer Cell Dormancy Mimics Embryonic Diapause285
Thyroid hormone suppresses medulloblastoma progression through promoting terminal differentiation of tumor cells285
A rational targeted therapy for platinum-resistant small-cell lung cancer267
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy264
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer263
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC251
Japan’s conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA250
KIT as a therapeutic target in neuroendocrine prostate cancer246
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies226
Adiposity and sex-specific cancer risk223
The KRAS mutational spectrum and its clinical implications in pancreatic cancer221
Evolutionary switch in expression of key markers between mouse and human leads to mis-assignment of cell types in developing adrenal medulla219
Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone219
Response to Kildsiute et al. and Bedoya-Reina and Schlisio206
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy203
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors203
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas203
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation202
Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese202
Meningeal lymphatics prime tumor immunity in glioblastoma198
Targeting APOBECs in cancer: It’s about timing196
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology192
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma189
Targeting the Microbiome to Overcome Resistance189
Resolving mutational signatures in cancer development189
Normal Somatic Mutations in Cancer Transformation188
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer184
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer179
Characterization of the generic mutant p53-rescue compounds in a broad range of assays177
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer175
Antihistamines for cancer immunotherapy: More than just treating allergies175
Seed or soil: Tracing the immune subsets in metastatic tumors175
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy170
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer170
Tumor organoids: Opportunities and challenges to guide precision medicine170
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer166
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer162
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance162
Proteogenomic and metabolomic characterization of human glioblastoma160
Less, but better: A simplified design for T cell redirection and conditional payload delivery158
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity157
Tracing back to one of the origins of immune evasion in pancreatic cancer155
Immune pressure sculps tumor cells and trims high-quality mutations154
Decoding tumor microenvironments through artificial tumor transcriptomes151
Transcription factor dependencies identify BAF-dependent cancers150
Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of immunosuppression in cancer148
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies147
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization146
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton145
Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital145
Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite144
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer144
PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay143
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy141
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients137
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer135
Progress and potential: The Cancer Moonshot135
Precision oncology across the ages: Impact on children, adolescents, and young adults134
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow133
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer129
Spark in the darkness: Discovering action potentials in brain tumors128
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer127
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade127
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies127
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations123
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions122
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis117
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition114
Spatial profiling technologies illuminate the tumor microenvironment113
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells113
A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity111
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers110
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers107
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity105
Deciphering the landscape of transcriptional heterogeneity across cancer104
Targeting pan-essential genes in cancer: Challenges and opportunities102
Developing and validating model systems for immuno-oncology101
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge101
Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings101
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer100
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy98
Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance98
Patterns of immune equilibrium and escape in indolent and progressing tumors95
0.13919591903687